Post-Brexit: impact in the Life Sciences sector (so far)
In a Q&A with European Pharmaceutical Review, Marie Manley, Partner at Sidley Austin and Will Holmes, Associate at Sidley Austin discuss the post-Brexit landscape for Life Sciences.
List view / Grid view
Articles
Formulation, Development & Delivery In-Depth Focus 2020
In this in-depth focus are features on how to succeed in the solid dosage form sector and the opportunities that nanoparticle drug delivery offers.
Manufacturing, Packaging & Logistics In-Depth Focus 2020
Included in this in-depth focus are articles examining the importance of child-resistant medicinal packaging and analysing whether continuous processing is the future for pharma.
The COVID-19 pandemic and the Indian pharmaceutical industry
Dr Abhishek Dadhich rounds up how the Indian pharmaceutical market has been impacted by the coronavirus pandemic and the steps the country’s government could take to overcome these setbacks.
Expert view: Improving the endotoxin test paradigm established by LAL
THE ADVANTAGES of the recombinant Factor C (rFC) test lie in its (a) scientific characterisation, (b) sustainability and (c) specificity. In light of diminishing horseshoe crab populations, sustainability has been mandated via regulations that include the concept of the “3 Rs”: replacement, reduction and refinement of analytical tests and reagents…
Guide to Testing
Welcome to European Pharmaceutical Review’s Guide to Testing. In this edition, Eurofins, Associates of Cape Cod, Inc. (ACC), SGS Life Sciences and Nelson Labs showcase their unique testing services and discuss how they stand out from the competition.
Bioprocessing & Bioproduction In-Depth Focus 2020
The articles in this in-depth focus discuss the importance of biosimilars and how liquid chromatography can be used to ensure the purity of lipid-based nanoparticles for drug delivery.
QA/QC & Analytical Techniques In-Depth Focus 2020 with a special focus on Chromatography & Microbiology
This in-depth focus highlights how liquid chromatography coupled to mass spectrometry (LC-MS) can be used to characterise proteins, what to do to improve regulatory compliance when using chromatography and the risks posed by underestimating bacterial contaminants in cleanrooms.
European Pharmaceutical Review Issue 2 2020
This issue focuses on the regulatory challenges associated with increased ventilator demand during COVID-19, as well as articles investigating the use of LC-MS for protein characterisation, improving efficiency with continuous processing and the risks posed by cleanroom contaminants. Other features discuss the continual evolution of solid dosage forms and the…
Stem cells in the clinic: how are they regulated?
Dr Roger Barker, University of Cambridge, UK and Eric Anthony, International Society for Stem Cell Research (ISSCR), describe how stem cells are regulated around the world and why this is important for patient safety.
Cutting the financial and time costs of regulatory affairs with automation
An exploration of how automation tools and AI could revolutionise the regulatory affairs sector with Ronan Brown, Senior Vice President and Head of Integrated Global Compliance at IQVIA.
Siltuximab – testing a potential COVID-19 therapy
Interim results from the SISCO study at the Papa Giovanni XXIII Hospital in Italy have demonstrated the promise of siltuximab as a treatment for the symptoms of COVID-19. Lee Morley explains how the drug works and the next steps for its development.
Productivity in pharma could be drastically improved with IoT implementation
Phoebe Chubb explores research that suggests laboratory productivity could be improved by 30 to 40 percent with digitalisation and IoT implementation.
COVID-19: regulatory implications for the UK and European life sciences industry
Marie Manley and co-authors from Sidley Austin explain the updates to regulations in the EU and UK in light of the COVID-19 coronavirus pandemic.
COVID-19 and big pharma: what are 15 leading companies doing to develop a coronavirus vaccine?
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
